Healthcare - Biotechnology - NASDAQ - US
$ 44.83
-3.9 %
$ 1.71 B
Market Cap
-10.05
P/E
BALANCE SHEET
265 M
ASSETS
68.5 M
LIABILITIES
197 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Tarsus Pharmaceuticals, Inc.
| Current Assets | 256 M |
| Cash & Short-Term Investments | 227 M |
| Receivables | 17.7 M |
| Other Current Assets | 11 M |
| Non-Current Assets | 9.36 M |
| Long-Term Investments | 631 K |
| PP&E | 3.35 M |
| Other Non-Current Assets | 5.38 M |
| Current Liabilities | 36.9 M |
| Accounts Payable | 18.1 M |
| Short-Term Debt | 398 K |
| Other Current Liabilities | 18.4 M |
| Non-Current Liabilities | 31.6 M |
| Long-Term Debt | 31.3 M |
| Other Non-Current Liabilities | 233 K |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Cash & Cash Equivalents | 224.9 | 71.7 | 171.3 | 168.1 | 58.0 | 2.4 |
| Short Term Investments | 2.5 | 145.4 | 0.5 | 0 | 0 | 0 |
| Receivables | 17.7 | 3.6 | 92 K | 20 K | 36 K | 4 K |
| Inventory | 3.1 | 4.8 | 0 | 0 | 20 K | 0 |
| Other Current Assets | 7.9 | 4.8 | 8.1 | 2.5 | 22 K | 24 K |
| Total Current Assets | 256.1 | 225.4 | 176.0 | 170.7 | 58.0 | 2.4 |
| PP&E | 3.3 | 1.5 | 1.8 | 1.2 | 0.3 | 6 K |
| Intangible Assets | 3.9 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 0.6 | 0.4 | 0.7 | 0 | 0 | 0 |
| Other Long Term Assets | 1.5 | 0.6 | 0.5 | 81 K | 6 K | 0 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 265.5 | 227.9 | 178.9 | 172.0 | 58.3 | 2.4 |
| LIABILITIES | ||||||
| Accounts Payable | 18.1 | 5.5 | 2.9 | 2.2 | 0.5 | 0.2 |
| Short Term Debt | 0.4 | 0.7 | 1.3 | 0.3 | 64 K | 0 |
| Other Current Liabilities | 18.4 | 9.2 | 7.3 | 2.9 | 0.3 | 4 K |
| Total Current Liabilities | 36.9 | 15.4 | 11.5 | 5.4 | 0.8 | 0.2 |
| Long Term Debt | 31.3 | 19.4 | 0.6 | 0.5 | 100 K | 0 |
| Deferred Tax Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0.2 | 100 K | 0.1 | 56 K | 63.4 | 3.6 |
| Total Liabilities | 68.5 | 35.0 | 12.2 | 6.0 | 64.3 | 3.7 |
| EQUITY | ||||||
| Common Stock | 5 K | 5 K | 4 K | 4 K | 2 K | 1 K |
| Retained Earnings | (244.7) | (108.8) | (46.7) | (32.8) | (6.0) | (1.4) |
| Other Accumulative Comprehensive Income/Loss | 2 K | 74 K | 0 | (172.0) | (63.4) | 1 K |
| Total Equity | 197.0 | 192.9 | 166.7 | 166.0 | (6.0) | (1.4) |
| Total Liabilities and Equity | 265.5 | 227.9 | 178.9 | 172.0 | 58.3 | 2.4 |
| SHARES OUTSTANDING | ||||||
| Common Shares Outstanding | 29.4 | 24.6 | 20.6 | 20.3 | 19.5 | 4.3 |